StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) company profile

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)

Close on Nov 17, 2026Market cap $43.60MP/E –Yield –

About Xilio Therapeutics

Pharmaceutical Preparations, SIC 2834

Xilio Therapeutics is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies for cancer treatment. Using proprietary protein engineering and masking technology, the company designs biologic therapies, including masked multi-specific molecules, engineered to activate selectively within the tumor microenvironment through tumor-specific proteases. These therapies aim to deliver localized therapeutic activity while minimizing the toxicities commonly caused by systemic exposure. The company develops programs for individuals living with cancer and engages in strategic collaboration and licensing agreements with biopharmaceutical partners, including Gilead Sciences and AbbVie.

The company operates its principal executive offices in Waltham, Massachusetts. Its activities also involve research, development, and manufacturing collaborations with global partners, including manufacturing and research operations conducted through WuXi Biologics in China. Corporate governance and business operations are conducted under Delaware jurisdiction.

Summary of the business section of Xilio Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Xilio Therapeutics, Inc.
Headquarters
Waltham, MA
Address
828 Winter Street 02451
Phone
(617) 833-1027
Employees
76, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
XLO
Exchange
Nasdaq
IPO date
Oct 22, 2021
Shares outstanding
6M, Mar 18, 2026
Public float
$34.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-14 reverse, Mar 16, 2026
SEC CIK
1840233
CUSIP
28422T209
ISIN
US28422T2093
FIGI
BBG00M4D4X92
Share class FIGI
BBG00M4D4XC8
EIN
85-1623397

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Rene RussoPRESIDENT AND CEO, Director325,422
Yariv HouvrasCHIEF MEDICAL OFFICER–
Christopher James FrankenfieldChief Financial Officer24,766
Kevin M. BrennanSVP, FINANCE AND ACCOUNTING6,371
Katarina LuptakovaCHIEF MEDICAL OFFICER33,250
Daniel J. CurranDirector–
Yuan XuDirector–
Robert W. RossDirector–
James Samuel ShannonDirector10,000
Aoife BrennanDirector–
Sara BonsteinDirector–
Akintunde Olatokumbo BelloDirector–
Cheryl R. BlanchardDirector–
Paul J. ClancyDirector–
Christina RossiDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
René Russo, Pharm.D.
President and Chief Executive Officer
$643.70K$128.74K$5.29M$371.74K$14.00K$6.45M+343%
Christopher Frankenfield
Chief Financial and Operating Officer
$533.10K$106.62K$2.29M$287.87K$14.00K$3.23M+212%
Katarina Luptakova, M.D.
Chief Medical Officer
$481.30K–$1.51M$196.37K$14.00K$2.20M+194%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 22, 2021
Offer price
$16.00
Securities offered
7,353,000
Gross proceeds
$117.65M
Exchange
Nasdaq
First trading day
Oct 22, 2021
First-day close
$16.00-0.0%
Lock-up ends (est.)
Apr 20, 2022

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 28, 2026, we had 76 full-time employees, including 30 employees with M.D., Pharm.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?